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1410 | Chem. Sci., 2013, 4, 1410–141Enzyme inhibition by metal complexes: concepts,
strategies and applications
Kelly J. Kilpin and Paul J. Dyson
Metal complexes are increasingly being used to inhibit enzymes. The reasons for this increased interest
arise from the special features that metal complexes oﬀer, e.g. the facile construction of 3D
architectures that tightly ﬁll enzyme active sites increasing selectivity and the possibility of facile
coordination to protein residues that enhances enzyme inhibition. In this review we classify the main
modes of enzyme inhibition by metal-based complexes and correlate the enzyme inhibition activity to
macroscopic properties such as anticancer activity.Rosenberg's discovery of the anticancer properties of cisplatin,
[cis-Pt(NH3)2Cl2],1 and its subsequent successful transition
into the clinic, changed the way in which inorganic
compounds were perceived in biological and medicinal
chemistry. In the ensuing years thousands of structurally
diﬀerent metal-based compounds have been synthesised and
evaluated for anti-cancer activity.2,3 However, and somewhat
disappointingly, from this vast selection of compounds, only
three (cisplatin, 1, and its descendants, carboplatin, 2, and
oxaliplatin, 3, Fig. 1), have progressed into worldwide clinical
use,4 although some new metal-based drugs are on the
horizon.5,6 Amongst the main reasons for this poor success
rate, with respect to both entering and successfully completing
clinical trials, are the low water solubility of many compounds
coupled to their high general toxicity. That is, in addition to
acting on cancer cells, healthy cells are also damaged, result-
ing in the undesirable side eﬀects oen associated with
chemotherapeutic treatments, and a consequence of
designing drugs that damage DNA. However, as our under-
standing of the pathways involved in the onset and progres-
sion of cancer increases, and the elds of genomics and
proteomics rapidly develop, the possibility to rationally design
compounds to specically target certain characteristics unique
to the disease also increases.7–9
The ultimate cellular target of cisplatin (and other Pt-based
clinical agents) is DNA,10 however in recent years other cellular
components have emerged as possible targets for metal-based
drugs.11–14 In particular, enzymes which play important roles in
metabolic pathways associated with cancer are proving popular
targets for metal-based drug design. This is not only true for
cancer chemotherapy, but has been extended to other diseases
of high social impact,15,16 and a number of reviews are dedicatedques, Ecole Polytechnique Fe´de´rale de
itzerland. E-mail: paul.dyson@ep.ch;
854
9toward metal-based enzyme inhibition, or more generally,
protein inhibition.8,17–21
We propose that metal-based enzyme inhibitors can be
classied into three main classes depending on the role the
metal centre plays in the inhibition process:
(1) Complexes that contain a metal centre that does not
directly coordinate to the enzyme. Instead, the ligands are the
biologically active component and are responsible for protein
binding/enzyme inhibition, although the metal may undergo
redox events that enhance these eﬀects.
(2) Complexes where the ligands merely mask a ‘naked’
metal ion, which usually, unselectively, interacts with many
diﬀerent protein targets. The ligands are usually not bioac-
tive, but are present to stabilise or protect the reactive metal
centre.
(3) Complexes where both the metal and the ligands are
biologically active and are mutually responsible for the biolog-
ical activity of the complex.
In this article we select examples of compounds that illus-
trate these three classications, with an emphasis on
complexes that have been rationally designed to selectively
inhibit specic enzymes involved in cancer. For more compre-
hensive reviews readers are directed towards the aforemen-
tioned literature. In addition, metal complexes that have been
designed to mimic enzyme activity, such a nucleases,22 prote-
ases23 and superoxide dismutases (SODs)24 are not covered in
this article.Fig. 1 Platinum-based anticancer agents in worldwide clinical use.
This journal is ª The Royal Society of Chemistry 2013
Fig. 3 Ferrocene and ruthenocene 1,2,3-triazole inhibitors of Carbonic Anhy-
drase (CA), with inhibition constants (Kis) in parenthesis (hCA II).
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View Article OnlineNon-coordinating metal centres, active
ligands
In pioneering studies, Jaouen successfully introduced redox
active ferrocenyl fragments into the structure of known organic
drugs.25,26 By replacing a phenyl ring on hydroxytamoxifen, 4,
(the active metabolite of the tamoxifen – a potent drug used for
the treatment of hormone dependent breast cancer) with a
ferrocene unit, a new series of drugs (hydroxyferrocifens, 5,
Fig. 2), were obtained. These ferrocenyl-derivatives demonstrate
signicantly diﬀerent activity proles to the original drug:
tamoxifen is only active against breast tumours which exhibit
estrogen receptors (ER(+)) whereas ferrocifens are also active
towards tumours which lack this receptor (ER()). Conse-
quently, the introduction of the metal fragment not only
increases the treatment spectrum, but also overcomes problems
associated with acquired resistance to tamoxifen.27,28 The
proposed mechanism involves docking of the organic moiety
into the receptor which is accompanied by two one-electron
oxidations to give a quinone methide structure which is capable
of forming adducts with biological nucleophiles.29 Such a
mechanism is highly dependent on the redox properties of the
ferrocene unit, thus the metal plays a role in the activity of the
drug without coordinating to the receptor. The concept of
introducing a ferrocenyl group was rapidly extended to the anti-
malarial drug ferroquine, 7, (currently in phase III clinical
trials), an analogue of chloroquine, 6, which is active against
both chloroquine-sensitive and resistant parasites (Fig. 2).30
Here it is not clear if the metal ion is active or inert, nevertheless
the modication results in uptake of the compound into resis-
tant bacteria and is not easily detoxied, thus overcoming
resistance. Although neither of these examples are active via
enzyme inhibition, they deserve to be mentioned, as they
elegantly demonstrate that the introduction of a metal fragment
can signicantly alter the activity proles of known drugs, andFig. 2 Clinically used organic drugs and ferrocene containing analogues.
This journal is ª The Royal Society of Chemistry 2013to varying degrees, provided the motivation for many of the
inhibitors that will be discussed in this article.
Two enzymes that are overexpressed in many types of cancer,
Carbonic Anhydrase (CA, specically the isoforms CA IX and CA
XII)31,32 and Histone Deacetylase (HDAC),33 are zinc-containing
metalloenzymes. In both enzymes the catalytic metal center is
located at the end of a barrel shaped hydrophobic cavity.
Typical organic inhibitors of these enzymes comprise a zinc
binding group (ZBG) such as a sulfonamide, a linker group
which interacts with the hydrophobic cavity of the enzyme, and
a tail group which is amenable to structural modication.
Poulsen and co-workers have evaluated the benet of intro-
ducing a metallocene, (either ferrocene or ruthenocene) onto
the tail of CA inhibitors, separated from the ZBG (a chelating
sulfonamide in this case) by either a 1,4-(8a, b) or a 1,5-1,2,3-
triazole (9a, b) spacer (Fig. 3).34–36 X-ray crystallography of the
complexes bound to the active site of human CA II (hCA II)
conrmed the binding of the sulfonamide to the catalytic zinc,
with the metallocene fragment located at the entrance to the
cavity and apparently uninvolved in any interactions with the
enzyme.35 Signicantly, the compounds modied with metal-
locenes were generally superior inhibitors than the analogues
containing a simple phenyl ring, and importantly, the metal-
based compounds displayed higher selectivity towards cancer
associated CA's over oﬀ-target CA's. The biopharmaceuticalFig. 4 Comparison of the space ﬁlling in the active site of hCA II by (a) 8a (PDB
3P55) and (b) 9a (PDB 3P44) highlighting how a slight change in geometry can
alter the ﬁt in the active site.35
Chem. Sci., 2013, 4, 1410–1419 | 1411
Fig. 7 A series of piano-stool Ru(II) arene CA inhibitors with inhibition constants
(nM, Kis) in parenthesis (hCA II).
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View Article Onlineproperties of the organic and metal-based drugs were shown to
be similar, suggesting the enhanced activity and isoform
discrimination of the metal-based drugs is due to the bulky
metallocene and its ability to occupy important regions of the
active site, inaccessible by more 2-dimensional organic
groups.36 However, the authors (and indeed others, vide infra)
point out that only slight perturbations to the metal group of
the inhibitor can result in signicant changes to the inhibition
activity. For example, the ruthenocene complexes (8b, 9b), in
which the two cyclopentadienyl (Cp) rings are slightly further
apart than in ferrocene, are better inhibitors than the analogous
ferrocene-containing species (8a, 9a) (Fig. 4).35
Alberto and co-workers have also investigated metal-based
CA inhibitors, this time introducing rhenium and technetium
tricarbonyl fragments onto the tail unit (Fig. 5).37 Like the
ferrocene-containing inhibitors of Poulsen, a co-crystal struc-
ture of 11a with hCA II showed the sulfonamide group bound to
the catalytically active zinc, and lacking interactions between
the CpRe(CO)3 substituted tail group and the protein (Fig. 6).
Interestingly, the compounds showed nanomolar aﬃnities for
particular CA subtypes, in particular compound 10 which
showed enhanced selectivity for the isoforms hCA II, IX and XIV,
a pattern of behaviour not observed for acetazolamide, a
benchmark organic inhibitor. This approach was extended with
the incorporation of technetium in place of rhenium (i.e.
CpTc(CO)3, viz. 11b) and as the inert
99mTc compounds exhibitFig. 5 Examples of metal-carbonyl CA inhibitors.
Fig. 6 Binding of 11a to hCA II determined by X-ray crystallography (PDB 3RJ7),
showing an intact Re coordination sphere and chelation of the active site zinc by
the sulfonamide group.37
1412 | Chem. Sci., 2013, 4, 1410–1419biological behaviour identical to their rhenium counterparts
this dyad has possible theranostic (i.e. therapeutic and diag-
nostic) applications.
A co-crystal structure of the same protein, hCA II, with the
ruthenium(II) piano stool complex 12c, bearing a sulfonamide
zinc binding group has also been reported.38 The complex
interacts with the protein in a manner reminiscent of the
previously described inhibitors; the sulfonamide group binds to
the catalytic zinc, the aryl spacer forms close contacts with the
hydrophobic funnel shaped cavity and the ruthenium arene
unit is positioned at the entrance of the cavity. There are no
ruthenium–protein interactions and the ruthenium coordina-
tion sphere remains intact, despite the presence of a chloride
leaving group. In accordance with previous observations, slight
changes to the arene ring greatly aﬀect the aﬃnity of the
complex for the enzyme, suggesting a subtle complementarity
between the metal unit and the enzyme (Fig. 7).
In a similar manner to that described for the CA inhibitors
above, the clinically used HDAC inhibitor SAHA, 13, (Vorinostat)
has been modied by replacement of the terminal phenyl ring
withmetal fragments (Fig. 8). Incorporation of a CpRe(CO)3 into
the SAHA backbone resulted in compounds (e.g. 14) that were
cytotoxic against a range of cell lines (ca. 12 mM), albeit slightly
less than SAHA (ca. 4 mM) itself, indicating that the introductionFig. 8 SAHA and metal-containing analogues evaluated as HDAC inhibitors.
This journal is ª The Royal Society of Chemistry 2013
Fig. 10 Examples of the protein kinase inhibitors with selected PAK-1 inhibition
parameters (measured in the presence of 1 mM ATP).8
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View Article Onlineof such steric bulk promotes less favourable enzyme–inhibitor
interactions (although the reduced cellular uptake of the metal-
containing complex compared with SAHA cannot be discounted
as a reason for the lower activity).39 Docking studies on the
ferrocene modied species JAHA, 15, alluded to the molecule
binding to the HDAC active site in a manner similar to SAHA.40
This proposition was subsequently corroborated when HDAC
inhibition assays revealed SAHA and JAHA display similar
nanomolar inhibition proles against a selection of HDAC
isozymes. As with the Re(CO)3 example, the cytotoxicities of
JAHA, and other structurally modied JAHAs, were slightly less
than that of SAHA itself.41
In contrast to modifying somewhat remote groups of organic
inhibitors, Meggers et al. have taken the concept of using metal
fragments to occupy dened regions of 3D-space in enzyme
active sites one step further. As opposed to attaching an inert
metal group to a known inhibitor, their concept was to use the
inert metal as a scaﬀold in which to orientate biologically active
ligands with well-dened topologies. Using this approach the
metal complexes behave like organic molecules with the inert
metal acting as a ‘hypervalent carbon’ atom with the metal
centre placed at the heart of the inhibitor. With the increased
coordination number and isomers available by virtue of the
typically octahedral metal centre (compared with carbon), the
complexes are able to occupy a dened region of 3D space,
which results in a greater selectivity of the inhibitor relative to
2D organic structures.42
The lead compounds of this class were designed to mimic
staurosporine, a complex natural product which acts as a
potent ATP-competitive protein kinase inhibitor. The metal-
based mimics retain the indolocarbazole core of staurosporine,
which interacts with the cle shaped kinase active site in a
manner similar to ATP, but the carbohydrate moiety is replaced
by an inert (typically) octahedral metal centre (Fig. 9). The
resulting complexes are amenable to extensive structural
modications, e.g. by modifying the ancillary ligands around
the metal.42
The initial complexes were shown to be inhibitors of Pim-1,43
and following a number of structural modications (driven by
structure based design, combinatorial chemistry, screening
libraries etc.) inhibitors which display nanomolar, and in someFig. 9 The natural product staurosporine and the metal-based mimics designed
as protein kinase inhibitors.
This journal is ª The Royal Society of Chemistry 2013cases picomolar kinase inhibitory properties, were obtained.
Slight structural modications resulted in substantial diﬀer-
ences in selectivity towards diﬀerent members of the kinase
family – discriminating between diﬀerent members of the
family with organic molecules is problematic due to the highly
conserved ATP binding sites.44–48
The biological impact of a slight modication on the ancil-
lary ligand is illustrated in Fig. 10, which shows that minor
modications at an apparently remote site lead to large
diﬀerences in inhibition values. This approach has been
extended to other metal centres, including platinum,49
osmium,50 iridium51 and rhodium.52,53 In addition to a number
of experiments used to demonstrate the inert character of the
metal, a number of co-crystal structures have been determined,
with the staurosporine mimics bound in the active site of the
kinase enzyme (e.g. 16a, Fig. 11).44–48,50,54–57 Regardless of the
kinase, interactions between the ligand and the active site,
which are reminiscent of ATP and staurosporine binding, are
retained. In all cases the metal ion plays a purely structural role,
and is not involved in any direct contacts with residues in the
active site, and therefore it can be considered to act as a type ofFig. 11 Co-crystal structure of 16a (L-FL172, PDB 3FXZ) and protein kinase PAK-
1 with 16a bound at the ATP-binding site of the enzyme (C-terminal domain),
showing the tight ﬁt of 16a with the hinge region of the enzyme.44
Chem. Sci., 2013, 4, 1410–1419 | 1413
Fig. 12 The Re(V) complex 18 with cathepsin IC50 inhibition (mM) values.
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View Article Onlineglue holding together diﬀerent ligands. This approach also
allows diversity to be easily introduced in the synthetic process,
allowing libraries of related inhibitors to be generated and
screened, facilitating the discovery of highly active and selective
enzyme inhibitors.54,58,59
Active metal centres
In the previous section, the examples describe cases where the
metal plays a structural role, allowing the inhibitors to occupy a
dened space in an enzymes' active site. At the opposite end of
the spectrum are those complexes where the ligand is essen-
tially biologically ‘innocent’, and the metal centre is entirely
responsible for the activity of the complex. There are a plethora
of examples in the literature of inorganic complexes where
metal ions with simple ligands inhibit enzymes, especially
relating to ‘so’ metal ions, namely Pt(II), Ru(III), Au(I) and
Au(III), that inhibit enzymes by binding with so donor atoms
on amino acid residues, typically the sulfur in cysteine residues,
at both active and allosteric sites. In particular, a number of
reviews describe the protein interactions of platinum and gold
drugs, showing that such interactions are critical to their mode
of action and that DNA is not the only relevant target.60,61 In
some cases however, the increased liability of the metal ion
allows a more complete exchange of the original ligands with
binding residues on potential biomolecular targets, which in
turn reduces selectivity and may account for the general toxicity
of the compounds. Take for example relatively simple Au(I)
thiolate complexes, such as auranon, 17, which is used in the
clinic to treat severe rheumatoid arthritis. Early studies on the
anticancer activity of auranon revealed activity levels similar to
cisplatin in vitro, which subsequently led to a large number of
Au(I) complexes being evaluated for anti-proliferative activity.62
Although the mechanism of action of these compounds is still
not fully understood, inhibition of enzymes seems to play a
major role.63 However, it appears that the compounds are non-
selective, and investigations have revealed that such
compounds not only inhibit a number of signicant enzymes
including thioredoxin reductase (TrxR),64 cysteine proteases,65
kinases66 and glutathione transferase (GST P1-1),67 but also
interact with other cysteine-rich proteins such as serum
albumin.68 In addition, Au(I) thiolate compounds also interact
with zinc nger proteins to trigger the release of zinc ions.69,70 In
these examples, the ligands appear to play a role in stabilising
or masking the reactive metal ion whilst transporting it through
the body to the nal target site, thus by altering the strength of
the metal–ligand interactions the reactivity of the complex can
be ne-tuned. This is a highly interesting strategy, but to the
best of our knowledge there are no examples where the ligand
has been designed to specically direct the metal ion towards,
and interact with, a specic enzyme.1414 | Chem. Sci., 2013, 4, 1410–1419There are also a few examples of compounds where the
‘innocent’ ligand is designed to remain coordinated to the
metal, and as seen with the inert complexes, the ligand can
aﬀect the selectivity of the complex. For example, the oxo-
rhenium(V) complex 18 (Fig. 12) was designed to selectively
inhibit the enzyme cathepsin B ahead of other members of the
family, taking advantage of the occluding loop that extends over
the active site of this enzyme. The tridentate sulphur ligand
stabilises the Re(V) centre and the chloride ligand undergoes
substitution with a thiol of the enzyme active site.71,72 The oxo-
rhenium(V) complex is not only a nanomolar inhibitor of the
enzyme, but is also 44-fold more selective for cathepsin B than
cathepsin K (Fig. 12).Active metal centres and active ligands
The concept of multi-targeted therapeutics to treat complex
diseases, such as cancer, is gaining in popularity due to the
ability of such a treatment regimens to attack the disease from
multiple angles.73 Thus, by linking active metal centres to bio-
logically active ligands, compounds capable of interacting with
multiple biological targets in a semi-targeted fashion, can be
accessed. Such hybrid complexes potentially oﬀer advantages
over drugs only capable of singular modes of action in that they
are oen more eﬃcient and less vulnerable to the defence
mechanisms of the disease. This approach, i.e. combining an
organic enzyme inhibitor that interacts with the enzyme via
non-covalent bonds, with a metal fragment that can directly
coordinate to the enzyme, also leads to stronger inhibitors that
are more likely to inhibit enzymes irreversibly. Such hybrid
inhibitors oﬀer several potential advantages including
increased eﬃciency of target disruption, increased duration of
action, and consequently less sensitivity toward pharmacoki-
netic parameters. However, if an inhibitor binds irreversibly to
its target then it is important that the target is unique or
signicantly over-expressed in the diseased cells to avoid severe
toxicity problems.
The potential of this class of compound was demonstrated
with rationally designed platinum compounds that target and
inhibit glutathione-S-transferase (GST).74 GST's are an impor-
tant class of enzymes which, among other things, are involved
in the detoxication and removal of toxic compounds from the
cell. In particular, GST P1-1 is implicated in drug resistance in
some forms of cancer and is overexpressed in certain cisplatin-
resistant tumours. Since reversal of this resistance can be ach-
ieved by inhibition of this enzyme, ethacraplatin, 20, which
combines a Pt(IV) centre and a known GST inhibitor, ethacrynic
acid (EA) 19, was developed (Fig. 13). Ethacraplatin was laterThis journal is ª The Royal Society of Chemistry 2013
Fig. 13 Ethacrynic acid (EA) and the ethacrynic acid–Pt(IV) complex, ethacra-
platin, designed to overcome cisplatin resistance by inhibition of glutathione-S-
transferase.
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View Article Onlineshown to have a mode of action partly similar to satraplatin, i.e.
involving in vivo reduction of Pt(IV) to the active Pt(II) centre, but
in the case of ethacraplatin this step occurs inside the GST
enzyme, with the two molecules of EA remaining within the
enzyme, thus introducing a mechanism to overcome cisplatin
resistance by the subsequent release of the Pt(II) ion. It was
demonstrated that ethacraplatin is a low micromolar inhibitor
of GST P1-1, more active than EA alone or in combination with
cisplatin. In addition, 20 also retains cytotoxicity levels similar
to cisplatin across a range of cell lines. A co-crystal structure of
ethacraplatin with wild-type GST P1-1 revealed the enzyme is
capable of activating and reducing the Pt centre, with both EA
and the Pt ion initially bound to the enzyme (Fig. 14).75
Using a similar approach, a SAHA–carboplatin conjugate, 21,
was developed with the rationale that combining a platinum
centre with an HDAC inhibitor could lead to a drug which is
active against a broader spectrum of cancers, and also overcome
drug resistance problems.76 In addition, SAHA has been shown
to have some selectivity towards cancer cells over healthy cells,Fig. 14 Structure of 20 bound to GST P1-1 showing cleavage of the Pt–EA
moieties, with EA located in the enzyme active site, with the Pt at the dimer
interface (PDB 3N9J).75
This journal is ª The Royal Society of Chemistry 2013so the inclusion of such amoiety could also tackle the selectivity
problems associated with current platinum based drugs. Car-
boplatin undergoes hydrolysis following cellular uptake, and it
was proposed that the hybrid would act in a similar way,
breaking apart in the nucleus to release the enzyme inhibitor
and platinum unit which could exert their eﬀects indepen-
dently. Indeed, the compound is capable of binding to nucleo-
tides and DNA in a similar manner to cisplatin, however, in a
cell free assay the hybrid was approximately 100 fold less active
than SAHA alone. In vitro cytotoxicity assays did not indicate any
synergistic eﬀects or improved activity against human ovarian
cancer cell lines although selectivity towards non-tumour lines
was observed.
One class of anti-cancer compounds which are promising
with respect to being specically toxic towards cancer cells are
the ruthenium(II) arene compounds which contain a PTA
ligand, 22, represented by the lead compound RAPTA-C 23
(Fig. 15).77,78 In contrast to Pt(II) drugs, RAPTA complexes favour
interactions with proteins rather than DNA. For example, 23 has
been shown to have a preference in the cell nucleus for histone
protein sites as opposed to DNA within the nucleosome, as
illustrated by the crystal structure of a ca. 200 kDa nucleosomeFig. 15 RAPTA-C and a selection of ruthenium(II) arene–EA conjugates.
Chem. Sci., 2013, 4, 1410–1419 | 1415
Fig. 17 A ruthenium(II) arene phenoxazine complex 27 designed as an MDR
inhibitor and the uncoordinated ligand 26.
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View Article Onlinecore particle soaked with 23.79 With this in mind, and taking
advantage of the robust nature of the RAPTA backbone, the
prototype compound has been modied to tune the activity of
the complexes.
Applying the approach described for the platinum–etha-
crynic acid derivative discussed above, the GST inhibitor EA was
tethered to the ruthenium arene scaﬀold (Fig. 15) via the arene
ring, e.g. 24 (to retain the similarity with RAPTA complexes), or
via an imadazole linker 25. Irrespective of the linking method,
the compounds were found to be good inhibitors of GST, with
IC50 values for the inhibition in the same order of magnitude as
EA (12.0 mM), whereas the prototype compound, RAPTA-C,
showed no inhibition of the enzyme up to 200 mM. In addition,
the Ru–EA complexes were considerably more cytotoxic than
RAPTA-C.80 Further experiments indicated that for the imid-
azole complexes (e.g. 25), the molecule binds to a cysteine
residue. A co-crystal structure of the RAPTA complex 24 with
GST P1-1 indeed showed the metallodrug bound to the enzyme
at the dimer interface, close to the thiol of Cys101. When the
enzyme was treated with 24 for a longer time (48 h compared to
24 h), EA was found bound to the active site but the ruthenium
was no longer present, consistent with mass spectrometric data
which indicates dissociation of 24 over time. Such an observa-
tion could explain the increased activity of Ru–EA compared to
RAPTA-C, as the ruthenium ion is released into a sensitised
cell (Fig. 16).
In attempts to address the problems associated with multi-
drug resistance (MDR), Ru(II) arene complexes were combined
with known inhibitors of the ATP-dependent eﬄux protein,
P-glycoprotein (Pgp), which is oen overexpressed in cancer
cells. Furthermore, as eﬄux pumps are oen non-specically
expressed in tumour cells, it was hoped that tethering MDR
modulators to ruthenium compounds would overcome non-
specicity, owing to the selective tumour-targeting properties of
certain ruthenium compounds. Phenoxazine-based inhibitors
were tethered to the ruthenium arene structure via an imidazole
linker, e.g. 27 (Fig. 17). In vitro assays revealed 27 retained
selectivity towards tumorigenic cell lines and in addition, also
inhibited Pgp, albeit less than verapamil (25%), an organic
compound in clinical trials as a MDR antagonist. The imidazole
ligand, phenoxide, 26, showed a comparable level of PgpFig. 16 Diagram showing the bonding between the ruthenium centre of 24 and
the two Cys101 residues of the individual monomers of GST P1-1 (PDB 3DD3).77
1416 | Chem. Sci., 2013, 4, 1410–1419inhibition, but was not selective towards tumour cell lines
indicating the ruthenium centre indeed confers some degree of
selectivity.81
Only recently, Nazarov and Dyson have reported on the
conjugation of lonidamine, 28, to the ruthenium arene core
(Fig. 18).82 Thus compounds such as 29 are expected to selec-
tively interfere with cellular energy processes, as lonidamine is
known to inhibit aerobic glycolysis in cancer cells whilst
simultaneously enhancing aerobic glycolysis in normal, or
healthy cells. Indeed, the hybrids show greater in vitro cytotox-
icity (IC50 ca. 20 mM) towards A2780 and A2780 cisplatin resis-
tant cell lines than lonidamine (IC50 ca. 200 mM), or a simple
ruthenium–imidazole conjugate (IC50 > 100 mM). In addition,
complex 29 shows moderate selectivity towards human glio-
blastoma cell lines relative to primary neuronal cultures of the
cerebral cortex.
In keeping with the theme of ruthenium(II) arene complexes,
Salmain et al. described how complexes with chloroacetamide
or maleimide groups tethered to the h6-bound arene ligand
could direct the complex to the active site of the cysteine
endoproteinase papain.83 Covalent binding of the complex to
the enzyme was demonstrated by biochemical and mass spec-
trometric studies. Related iron-carbonyl derivatives were shown
to behave in a related fashion,84 and other maleimide deriva-
tives were shown to bind to thiol-containing biomolecules.85
Hartinger et al. have recently reported a series of complexes
(30a–d) designed with a dual mode of action, exerting their
eﬀects by binding to DNA (via the ruthenium centre) whilst alsoFig. 18 Lonidamine 28, and an example of a ruthenium(II) arene–lonidamine
hybrid 29 designed to inhibit cellular energy processes.
This journal is ª The Royal Society of Chemistry 2013
Fig. 19 Examples of ruthenium(II) arene complexes with multiple modes of
action.
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View Article Onlineinhibiting the enzyme topoisomerase II (via intercalation of the
attached avone ligand).86–88 In separate experiments, DNA
binding and topoisomerase II inhibition (20–40 mM) was
demonstrated, with the complexes acting as better inhibitors
than the avone ligands alone (>40 mM). Moreover, the cyto-
toxicity (low mM range) and topoisomerase inhibitory activity
correlate well, suggesting their mechanism of action may
involve inhibition of the enzyme. Although these are not the
rst examples of Ru-based topoisomerase inhibitors (or metal-
based topoisomerase inhibitors), the authors were the rst to
demonstrate that the metal has an additional role to play in the
mechanism by being able to interact with DNA. A series of
ruthenium–naphthalimide conjugates 31 exert a related mech-
anism, i.e. the ruthenium centre interacts preferentially with
proteins, leaving the naphthalimide unit free to intercalate to
DNA. The enhanced cytotoxicity of the conjugates, compared
with RAPTA-C, suggest an additional mechanism of action takes
place, and on the basis of the intercalating behaviour of the
naphthalimide unit, inhibition of topoisomerase cannot be
discounted.89 A number of cytotoxic metal(II) arene complexes
(metal¼ Ru and Os) with paullone ligands that exert their eﬀect
via the inhibition of kinases have also been reported
(Fig. 19).90–92
Lastly, and although their mode of action is unclear, non-
steroidal anti-inammatory drugs (NSAIDs), in particular
aspirin 32, are being investigated as possible chemotherapeutic
agents. It is believed they exert their eﬀects via interruption of
pathways associated with cyclooxygenase (COX) enzymes,
especially COX-1 in the case of aspirin. However, the biologicalFig. 20 The indiscriminate COX-1 and COX-2 inhibitor, 33 and the parent
organic compound, aspirin 32.
This journal is ª The Royal Society of Chemistry 2013properties of the aspirin–hexacarbonyldicobalt conjugate 33
(Fig. 20)93 are signicantly diﬀerent from aspirin.34 Aspirin
preferentially inhibits the enzyme COX-1 whereas 33 fails to
discriminate between COX-1 and COX-2, which in turn is over-
expressed in various tumours. In addition, 33 shows an activity
prole similar to cisplatin across a range of cell lines.93,94
Although 33 has many sites susceptible to nucleophilic attack it
is stable under in vitro conditions, suggesting the complex
remains intact, and is responsible as a whole for the biological
activity,95 probably via direct interaction with the enzyme and
disruption of its expression. Further recent studies with zebra
sh embryos also indicate that 33 also has anti-angiogenic
properties, a trait which is not present with aspirin.96Conclusions
The main ways in which metal complexes can inhibit enzymes
have been categorized and illustrated with representative
examples. Traditional metal-based drugs target DNA and
simultaneously bind to many diﬀerent proteins, but in this
review we show that well designed metal complexes can exhibit
higher degrees of selectivity relative to organic inhibitors and
may also bemore eﬃcient inhibitors due to direct coordination.
These complexes can be used as useful tools in chemical
biology. However, since the emerging drugs used to treat
diseases such as cancer are increasingly based on the inhibition
of specic targets and pathways, there is clearly much promise
for metal complexes that selectively inhibit enzymes in medic-
inal chemistry to treat a wide range of diseases. Future research
may focus on non-toxic metals that are better detoxied and
may have superior pharmacological proles, especially when
the metal is used as a scaﬀold. For active metals combined with
organic inhibitors a more detailed mechanistic understanding
of the role of coordination is required to establish the advan-
tages and potential disadvantages of such systems at a molec-
ular level. Approaches that allow the inclusion of structural
diversity in a facile manner are also likely to become more
widespread as this approach signicantly increases the chances
of discovering useful compounds.Acknowledgements
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